Skip to content

Treatment Off Gingival Recession Defects Using a Xenogenic Acellular Dermal Matrix Compared to Connective Tissue Graft.

Treatment of Multiple Gingival Recession Defects Using a Xenogenic Acellular Dermal Matrix Compared to Connective Tissue Graft: a Randomized Controlled Clinical Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03162016
Acronym
MUCODERM
Enrollment
12
Registered
2017-05-22
Start date
2017-06-23
Completion date
2020-09-07
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival Recession

Brief summary

Limitation of donor site and significant postoperative morbidity are often described in connective tissue graft harvesting. We want to show if mucoderm used in tunnel technique to recover miller class I and II recessions defects could be an alternative to connective tissue graft.

Detailed description

Connective tissue graft harvested from the palate does not always have sufficient size to cover multiple recession defects. Moreover, connective tissue graft shows significant postoperative morbidity to treat generalized multiple gingival recessions. The goal of this study is to show if Mucoderm could be considered has a substitute of connective tissue graft in the coverage of gingival recession defects.

Interventions

PROCEDUREtransplants

Transplant of palatine tissue and transplant of connective tissue Mucoderm

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \> 45 years, postmenopausal women (ie with amenorrhea for more than a year). * Subject with bilateral Miller class I or II recessions defects * non smoking patients * patients having read and understood the information note on the study and signed the informed consent form. * patients affiliated to the social security system.

Exclusion criteria

* Patient with absolute contra-indication for dental surgery: valvular heart disease at risk of infectious endocarditis, recent myocardal (≤ 12 months), organ transplants, recent placement of a coronary stent (≤ 12 months), transient ischemic attacks recurrent, cardiovascular instability, uncontrolled epilepsy, rheumatic fever. * Patient with metabolic bone disease (Paget's disease, osteomalacia, osteogenesis imperfecta) * Patient with an ASA score ≥ 3. * Patient with absolute contra-indication to dental surgery * Patient with severe hematologic disease * Patient with I or type II diabetes * Patients with previous or current acute illness or severe chronic cardiovascular, renal, hepatic, gastrointestinal, allergic, endocrine, neuro-psychiatric, considered by the investigator to be incompatible with the conduct of the study. * Patients treated with retinoids, oral bisphosphonates, oral anticoagulants or anticonvulsants. * Patient have or have had cancer of the upper aerodigestive tract treated by radiotherapy. * Patient taking a steroidal or non-steroidal anti-inflammatory, anti-cancer or immunosuppressive chemotherapy in the last 6 months. * Patient monitoring considered difficult by the investigator. * Patient with poor oral hygiene incompatible with oral surgery. * Patients with periodontal disease unstabilized * Patient with oral dermatitis or adverse occlusion. * Patient with an acute or chronic infection of the surgical site (osteomyelitis). * Patient with a known allergy to collagen * Patient with autoimmune disease * Patient with a linguistic or mental incapacity to understand information * Patient younger than 45 years old * Patient trust under curatorship or judicial protection * Patients aged over 45 premenopausal. * Patient participating in another clinical study.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Root coverageat 6 monthComparison of Percentage of Root coverage at baseline and 6 months postoperatively

Secondary

MeasureTime frameDescription
postoperation painat day 1 postoperationvisual analogic scale (at control and test side),

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026